Table 2

Prevalence, consequence and treatment of myelosuppression and FN in the study and control groups, and in long-acting and short-acting G-CSF users

Chemotherapy cycles in study group (n=182)Chemotherapy cycles in control group (n=483)P valueChemotherapy cycles of long-acting G-CSF utilisation (n=258)Chemotherapy cycles of only short-acting G-CSF utilisation (n=347)P value
Short-acting G-CSF utilisation, n (%)79 (43.4%)230 (54.4%)0.01395 (36.8%)214 (61.7%)<0.001
 Doses, mean±SD1.0±1.72.0±2.6<0.0010.8±1.62.3±2.7<0.001
Clinical visits, mean±SD
 Visits to ER0.3±0.91.0±1.8<0.0010.5±1.21.0±1.8<0.001
 Visits to outpatient clinics1.8±1.32.5±1.4<0.0012.0±1.32.5±1.5<0.001
 All visits2.1±1.73.5±2.5<0.0012.5±1.93.5±2.6<0.001
CBC times, mean±SD5.0±1.95.3±2.10.1924.9±2.05.4±2.10.003
FN, n (%)5 (2.7%)33 (7.8%)0.0197 (2.7%)31 (8.9%)0.002
 Lasting duration (day), mean±SD1.8±0.8 (n=5)1.3±0.6 (n=33)0.2891.7±0.8 (n=7)1.3±0.6 (n=31)0.171
 Admission for FN, n (%)3/5 (60%)22/33 (66.7%)0.5674/7 (57.1%)21/31 (67.7%)0.451
 Antibiotics for FN, n (%)5/5 (100.0%)27/33 (81.8%)0.4017/7 (100.0%)25/31 (0.267%)0.267
Myelosuppression, n (%)
 All79 (43.4%)292 (69.0%)<0.001113 (43.8%)258 (74.4%)<0.001
 Grade 3/436 (19.8%)174 (41.1%)<0.00147 (18.2%)163 (47.0%)<0.001
 Grade 412 (6.6%)73 (17.3%)<0.00115 (5.8%)70 (20.2%)<0.001
G-CSF-associated pain, n (%)60/182 (33.0%)200/423 (47.3%)0.00196/223 (43.0%)164/221 (74.2%)<0.001
 VAS, mean±SD1.8±2.61.4±2.00.2141.7±2.41.4±2.00.150
Skin rash, n (%)4/182 (2.2%)6/421 (1.4%)0.3555/258 (1.9%)5/347 (1.4%)0.434
Delay of chemotherapy, n (%)17 (9.3%)50 (11.8%)0.37323 (8.9%)44 (12.7%)0.144
 Delayed days, mean±SD0.5±2.20.5±1.90.9300.4±2.00.5±1.90.162
  • CBC, complete blood count; ER, emergency room; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; VAS, visual analogue scale.